New articles from the NIH

[Magnus1964]

New from the NIH

1.

The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.

Zhang X, Zhang G, Wang J, Bi J.

Front Endocrinol (Lausanne). 2023 Feb 10;14:1131033. doi: 10.3389/fendo.2023.1131033. eCollection 2023.

PMID: 36843606 Free PMC article.

2.

Association between Alcohol Intake and Prostate Cancer Mortality and Survival.

D'Ecclesiis O, Pastore E, Gandini S, Caini S, Marvaso G, Jereczek-Fossa BA, Corrao G, Raimondi S, Bellerba F, Ciceri S, Latella M, Cavalcabò NB, Bendinelli B, Saieva C, Fontana M, Gnagnarella P.

Nutrients. 2023 Feb 12;15(4):925. doi: 10.3390/nu15040925.

PMID: 36839283 Free PMC article. Review.

3.

Association of TLR4 gene 2026A/G (rs1927914), 896A/G (rs4986790), and 1196C/T (rs4986791) polymorphisms and cancer susceptibility: Meta-analysis and trial sequential analysis.

Wang F, Wen X, Wen T, Liu Z.

Medicine (Baltimore). 2023 Feb 22;102(8):e33040. doi: 10.1097/MD.0000000000033040.

PMID: 36827055

4.

C-reactive protein levels could be a prognosis predictor of prostate cancer: A meta-analysis.

Zhou K, Li C, Chen T, Zhang X, Ma B.

Front Endocrinol (Lausanne). 2023 Feb 3;14:1111277. doi: 10.3389/fendo.2023.1111277. eCollection 2023.

PMID: 36817592 Free PMC article.

5.

The Role of C-Reactive Protein in the Prognosis of Prostate Cancer: A Meta-Analysis.

Liu T, Zhuo L.

J Environ Public Health. 2023 Feb 2;2023:6222324. doi: 10.1155/2023/6222324. eCollection 2023.

PMID: 36776544 Free PMC article.

6.

Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance.

Peng G, Wang C, Wang H, Qu M, Dong K, Yu Y, Jiang Y, Gan S, Gao X.

Oncoimmunology. 2023 Feb 6;12(1):2173422. doi: 10.1080/2162402X.2023.2173422. eCollection 2023.

PMID: 36776524 Free PMC article. Clinical Trial.

7.

Prognostic value of the pretreatment systemic immune-inflammation index in patients with prostate cancer: a systematic review and meta-analysis.

Meng L, Yang Y, Hu X, Zhang R, Li X.

J Transl Med. 2023 Feb 4;21(1):79. doi: 10.1186/s12967-023-03924-y.

PMID: 36739407 Free PMC article. Review.

8.

Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis.

Chen J, Yuan Y, Fang M, Zhu Y, Sun X, Lou Y, Xin Y, Zhou F.

Front Endocrinol (Lausanne). 2023 Jan 17;13:1074540. doi: 10.3389/fendo.2022.1074540. eCollection 2022.

PMID: 36733800 Free PMC article.

9.

A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases.

Thellenberg-Karlsson C, Vjaters E, Kase M, Tammela T, Ojamaa K, Norming U, Nyman C, Andersson SO, Hublarovs O, Marquez-Holmberg M, Castellanos E, Ullen A, Holmberg A, Nilsson S.

Eur J Cancer. 2023 Mar;181:198-207. doi: 10.1016/j.ejca.2022.12.006. Epub 2022 Dec 20.

PMID: 36682096 Clinical Trial.

10.

A prospective randomized controlled trial comparing target prostate biopsy alone approach vs. target plus standard in naïve patients with positive mpMRI.

Porpiglia F, Checcucci E, DE Cillis S, Piramide F, Amparore D, Piana A, Volpi G, Granato S, Zamengo D, Stura I, Alladio E, Migliaretti G, DE Luca S, Bollito E, Gned D, DI Dio M, Autorino R, Manfredi M, Fiori C.

Minerva Urol Nephrol. 2023 Feb;75(1):31-41. doi: 10.23736/S2724-6051.22.05189-8. Epub 2023 Jan 10.

PMID: 36626117 Clinical Trial.

[Magnus1964]

If you wish to read any of these articles copy the "doi:" number and paste it in your web browsers location bar.

Magnus

[Papillon2 in reply to Magnus1964]

Thnx.